EA201201514A1 - Лечение аутоиммунных заболеваний - Google Patents

Лечение аутоиммунных заболеваний

Info

Publication number
EA201201514A1
EA201201514A1 EA201201514A EA201201514A EA201201514A1 EA 201201514 A1 EA201201514 A1 EA 201201514A1 EA 201201514 A EA201201514 A EA 201201514A EA 201201514 A EA201201514 A EA 201201514A EA 201201514 A1 EA201201514 A1 EA 201201514A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
alkoxy
halogen
phenyl
trihalogenomethyl
Prior art date
Application number
EA201201514A
Other languages
English (en)
Russian (ru)
Inventor
Петер Гергели
Эрик Валлстрём
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201514(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201201514A1 publication Critical patent/EA201201514A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/30Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA201201514A 2010-05-06 2011-05-05 Лечение аутоиммунных заболеваний EA201201514A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10162079 2010-05-06
PCT/EP2011/057203 WO2011138393A1 (en) 2010-05-06 2011-05-05 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
EA201201514A1 true EA201201514A1 (ru) 2013-05-30

Family

ID=42199281

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201514A EA201201514A1 (ru) 2010-05-06 2011-05-05 Лечение аутоиммунных заболеваний

Country Status (24)

Country Link
US (1) US20130172297A1 (enExample)
EP (1) EP2566470A1 (enExample)
JP (1) JP2013530937A (enExample)
KR (1) KR20130066630A (enExample)
CN (1) CN102869353A (enExample)
AU (1) AU2011249784B2 (enExample)
BR (1) BR112012028190A2 (enExample)
CA (1) CA2795394A1 (enExample)
CL (1) CL2012003091A1 (enExample)
CR (1) CR20120566A (enExample)
CU (1) CU20120154A7 (enExample)
EA (1) EA201201514A1 (enExample)
EC (1) ECSP12012312A (enExample)
IL (1) IL222690A0 (enExample)
MA (1) MA34285B1 (enExample)
MX (1) MX2012012926A (enExample)
NZ (1) NZ603999A (enExample)
PE (1) PE20130612A1 (enExample)
PH (1) PH12012502418A1 (enExample)
SG (1) SG185746A1 (enExample)
TN (1) TN2012000509A1 (enExample)
TW (1) TW201201814A (enExample)
WO (1) WO2011138393A1 (enExample)
ZA (1) ZA201207710B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
WO2004074297A1 (ja) * 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
ES2351393T3 (es) * 2003-05-26 2011-02-03 Takeda Pharmaceutical Company Limited Sulfopirroles.
MXPA06002349A (es) 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
CN1918148B (zh) * 2004-02-11 2012-09-05 巴斯利尔药物股份公司 取代的苯并咪唑和它们诱导细胞凋亡的用途
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
CA2820510A1 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases

Also Published As

Publication number Publication date
ECSP12012312A (es) 2012-12-28
AU2011249784A1 (en) 2012-12-20
TN2012000509A1 (en) 2014-04-01
CA2795394A1 (en) 2011-11-10
KR20130066630A (ko) 2013-06-20
TW201201814A (en) 2012-01-16
AU2011249784B2 (en) 2014-03-06
WO2011138393A1 (en) 2011-11-10
CN102869353A (zh) 2013-01-09
PH12012502418A1 (en) 2018-03-21
SG185746A1 (en) 2013-01-30
ZA201207710B (en) 2013-06-26
NZ603999A (en) 2014-06-27
PE20130612A1 (es) 2013-06-06
CU20120154A7 (es) 2013-03-27
MA34285B1 (fr) 2013-06-01
IL222690A0 (en) 2012-12-31
US20130172297A1 (en) 2013-07-04
CR20120566A (es) 2013-01-09
CL2012003091A1 (es) 2013-03-22
BR112012028190A2 (pt) 2016-08-02
MX2012012926A (es) 2012-12-17
JP2013530937A (ja) 2013-08-01
EP2566470A1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
MX375261B (es) Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca.
JP2013518050A5 (enExample)
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
JP2012506389A5 (enExample)
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
CY1117085T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
JP2016518437A5 (enExample)
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
EA200970856A1 (ru) Ингибиторы пути хеджхога
MX347616B (es) Inhibidores de csf-1r para el tratamiento de tumores de cerebro.
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
EA201691939A1 (ru) Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
EA201170456A1 (ru) Синергические комбинации макроциклического ингибитора вируса гепатита с и нуклеозида
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201000120A1 (ru) Фармацевтические композиции, содержащие холиновые соли янтарной кислоты, для интраназального введения
CN113784970A (zh) Erk抑制剂及其应用
MY199779A (en) Pyrrolopyrimidine compound and use thereof
MX2014003803A (es) Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
RU2016136193A (ru) Аминокарбонилкарбаматные соединения
EA022994B1 (ru) Способ подавления толерантности к опиоидному анальгетику
UY31824A (es) Nuevos compuestos
EA201201514A1 (ru) Лечение аутоиммунных заболеваний